Cardinal Health Inc CAH reported second-quarter FY24 adjusted EPS of $1.82, up 38% Y/Y, beating the consensus of $1.60.
Sales increased 12% to $57.45 billion, beating the consensus of $57.01 billion.
The second-quarter revenue for the pharmaceutical segment increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical sales growth from existing customers.
The Medical segment increased by 3% to $3.9 billion, driven by growth in at-home Solutions and Global Medical Products and Distribution, primarily reflecting higher Cardinal Health Brand volumes.
As announced earlier, the company completed a review of growth businesses within the Medical Segment, including investing in and further developing at-home Solutions and OptiFreight Logistics.
Wednesday, Cardinal Health agreed to acquire Specialty Networks, a technology-enabled multi-specialty group purchasing and practice enhancement organization, for $1.2 billion in cash.
The transaction creates increased clinical and economic value for 11,500 specialty providers, including over 7,000 physicians across 1,200 independent physician practices.
The deal creates a platform for Cardinal Health’s expansion across specialty therapeutic areas.
Outlook: Cardinal Health raised its FY24 adjusted EPS guidance to $7.20-$7.35 from prior guidance of $6.75-$7.00 versus consensus of $6.96.
The company forecasts 2024 Pharmaceutical and Specialty Solutions sales growth of 10%-12% from 2023 sales of $188 billion.
The company expects GMPD segment sales growth of around 2% Y/Y from 2023 at around $12.1 billion.
Price Action: CAH shares are down 4.30% at $104.49 on the last check Thursday.
Photo via Company
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.